- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02113878
Étude de phase Ib du BKM120 avec cisplatine et XRT dans le cancer épidermoïde localement avancé à haut risque de la tête et du cou
Une étude de phase Ib du BKM120 avec cisplatine hebdomadaire et radiothérapie dans le cancer épidermoïde localement avancé à haut risque de la tête et du cou
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
- This phase Ib study is combining standard chemoradiotherapy with weekly cisplatin and BKM120 to assess tolerability of this combination in high risk patients with locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). The investigators will also obtain preliminary information about the efficacy of this treatment.
- The participant will receive the study drug buparlisib once daily, by mouth, for 45 days. The participant will be given a study drug-dosing diary for each cycle. It will include special instructions for taking the study drug at home.
- The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study before and how well they have tolerated their doses.
- All participants will receive weekly cisplatin injection. Cisplatin will be given intra-venously (IV) on days: (1, 8, 15, 22, 29, 36 and 43) at DFCI.
- All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks, delivered at DFCI. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor.
- The investigators would like to keep track of the participant's medical condition. Follow-up will continue every 4 to 12 weeks after the end of treatment for the first year and at the investigator's discretion thereafter.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Dana-Farber Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent.
- Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented SCC of the cervical lymph nodes, with unknown primaries.
- >10 pack years of tobacco use
- Age ≥ 18 years
- ECOG performance status ≤ 2
- At least one site of measurable disease
- Adequate bone marrow function as shown by: ANC > 1.5 x 109/L, Platelets >100 x 109/L, Hb >9 g/dL
- Total calcium (corrected for serum albumin) within normal limits
- Magnesium ≥ the lower limit of normal
- Potassium within normal limits for the institution.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
- Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
- Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min
- Serum amylase ≤ ULN
- Serum lipase ≤ ULN
- Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)
- Signed informed consent
- INR ≤ 2
Exclusion Criteria:
- Distant metastatic disease
- Less than or equal to 10 pack years of tobacco history
- Received prior chemotherapy
- Received prior radiation to the head and neck or adjacent anatomical site
- Received prior treatment with a P13K inhibitor.
- Known hypersensitivity to BKM120 or to its excipients
- Acute or chronic liver, renal disease or pancreatitis
- Mood disorders ≥ CTCAE grade 3
- Diarrhea ≥ CTCAE grade 2
- Active cardiac disease
- History of cardiac dysfunction including any of the following:
- Patient has poorly
- Impairment of gastrointestinal (GI) function
- Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.
- Chronic treatment with steroids or another immunosuppressive agent.
- Herbal medications and certain fruits within 7 days prior to starting study drug.
- Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Appendix B for a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak inhibitors of CYP3A is allowed).
- Undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant.
- Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control.
- Known diagnosis of human immunodeficiency virus (HIV) infection
- History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dose Level 1
|
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Autres noms:
Cisplatin is a chemotherapy drug
Autres noms:
IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Autres noms:
|
|
Expérimental: Dose Level 2
|
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Autres noms:
Cisplatin is a chemotherapy drug
Autres noms:
IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum Tolerated Dose of Cisplatin
Délai: While on treatment, up to 66 days
|
The trial uses 3+3 design to determine maximum tolerated dose (MTD). |
While on treatment, up to 66 days
|
|
Maximum Tolerated Dose of BKM120
Délai: While on treatment, up to 66 days
|
The trial uses 3+3 design to determine maximum tolerated dose (MTD). |
While on treatment, up to 66 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Best Overall Response
Délai: Measured at end of treatment, up to 66 days
|
The best overall response for each patient is given per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) criteria: Complete Response (CR) - Disappearance of all target and non-target lesions and lymph node short axis is <10 mm and no new lesions Partial Response (PR)
Stable Disease (SD) - Less than 5 mm increase in target lesion diameter unless it results in a >=20% increase in diameter and >=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions Progressive Disease (PD)
|
Measured at end of treatment, up to 66 days
|
|
Median Time to Progression
Délai: Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
|
The median amount of time from baseline to progression and/or death. Patients known to be alive at last contact are censored at last contact. All patients alive at 24 months from baseline are censored at 24 months. |
Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
|
|
24 Month Overall Survival
Délai: Up to 24 months
|
The probability of survival at 24 months using Kaplan-Meier estimates. Patients alive at 2 years are censored at 2 years. |
Up to 24 months
|
|
Median Anxiety Score Change
Délai: From baseline to cycle 9, up to 66 days.
|
The median change in score on the Generalized Anxiety Disorder - 7 (GAD-7) questionnaire from baseline to cycle 9.GAD-7 has 7 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 21. Higher score represents worse anxiety. |
From baseline to cycle 9, up to 66 days.
|
|
Median Depression Score Change
Délai: From baseline to cycle 9, up to 66 days.
|
The median change in score on the Patient Health Questionnaire - 9 (PHQ-8) from baseline to cycle 9. PHQ-9 has 9 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 27. Higher score represents worse depression. |
From baseline to cycle 9, up to 66 days.
|
|
P13K Status by Response
Délai: Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.
|
Phosphoinositide 3-kinase (PI3K) biomarker status, either positive or negative, analyzed using established methods from tumor biopsies. P13K status is reported by response, either responder (CR or PR) or non-responder (SD or PR). |
Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Robert Haddad, MD, Brigham and Women's Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies stomatognathiques
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Tumeurs des voies respiratoires
- Carcinome
- Maladies oto-rhino-laryngologiques
- Tumeurs pharyngées
- Tumeurs oto-rhino-laryngologiques
- Maladies nasopharyngées
- Maladies pharyngées
- Carcinome épidermoïde
- Maladies laryngées
- Carcinome épidermoïde de la tête et du cou
- Tumeurs du nasopharynx
- Tumeurs laryngées
- Tumeurs hypopharyngées
- Thérapeutique
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Composés en platine
- Radiothérapie
- Radiothérapie, conforme
- Radiothérapie, assistée par ordinateur
- Cisplatine
- Radiothérapie, intensité modulée
- NVP-BKM120
Autres numéros d'identification d'étude
- 14-008
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
There are no plans to share the IPD. Cumulative data will be published however.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .